{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-012603","form_type":"8-K","ticker":"MIRA","cik":"0001904286","company_name":"MIRA PHARMACEUTICALS, INC.","filed_at":"2025-05-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.439354+00:00","generated_at":"2026-05-20T08:52:22.393772+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"MIRA updates on Ketamir-2 Phase 1 progress, plans Phase IIa in neuropathic pain by end of 2025","bullets":["Participating in BIO International Convention June 16-19, 2025 for partnering and licensing discussions.","Second dosing cohort of Ketamir-2 Phase 1 completed; company preparing to initiate third cohort.","Phase IIa trial in neuropathic pain expected to start by end of 2025.","Preclinical studies ongoing for PTSD and topical formulation for localized inflammatory pain.","Finalizing regulatory filings for SKNY acquisition; SKNY-1 targets smoking cessation and obesity."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-012603","json":"https://secwatch.observer/filing/0001641172-25-012603.json","markdown":"https://secwatch.observer/filing/0001641172-25-012603.md","text":"https://secwatch.observer/filing/0001641172-25-012603.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1904286/000164117225012603/0001641172-25-012603-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1904286/000164117225012603/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T08:52:22.393772+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}